CION Ameerpet
Immunotherapy · Gut & Liver Immune Reactions
Hepatitis B or C and Immunotherapy — What Changes
If you already have hepatitis B or C, immunotherapy is not automatically ruled out — but it does change how your treatment is screened and monitored. Reactivation of hepatitis B, in particular, is a recognised risk, which is why screening happens before your first dose, not after.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist (MBBS · MD · DM Medical Oncology, Adyar, Chennai · ECMO · MRCP SCE, UK) · Last reviewed August 2026
- Screening comes first — Hepatitis B and C blood tests are done before immunotherapy starts, not after, so your risk is known from day one.
- Not a blanket exclusion — Most patients with well-managed hepatitis B or C can still receive immunotherapy, with the right precautions in place.
- Know the red flags — Yellow eyes or skin, dark urine, or new fatigue during treatment need a same-day call to your oncology team.
- Monitored throughout — Liver function is rechecked before every cycle, so a flare is caught early rather than found late.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
If you notice these signs
Do I need to call my oncology team about liver symptoms if I have hepatitis B or C on immunotherapy?
Yes — call your oncology team, or CION's helpline, the same day if you notice yellowing of the eyes or skin, dark urine, pale stools, new itching, loss of appetite or unusual tiredness while on immunotherapy. Whether it turns out to be a viral flare or a separate immune reaction, both need same-day blood tests, not a wait-and-see approach at home.
Call Us: 1800-202-8726
- Yellow tinge to the eyes or skin (jaundice)
- Dark urine or unusually pale, clay-coloured stools
- New, unexplained itching over the body
- Loss of appetite, nausea, or discomfort under the right ribs
- Extreme tiredness that is new and does not match your usual pattern
A viral flare and an immune reaction caused by immunotherapy can look identical from the outside — only a same-day blood test tells your team which one it is and what to do next.
Did you know?
India carries one of the largest populations of people with undiagnosed chronic hepatitis B in the world. A routine pre-immunotherapy screening blood test is often the first time a patient learns their hepatitis B status — not because of any symptoms.
Timing matters
When does hepatitis B or C screening and monitoring happen around immunotherapy?
Screening happens once, at baseline, before your first dose. Monitoring for a possible flare then continues for as long as you remain on treatment, following the same rechecking pattern already used for every immunotherapy patient's liver function.
| Point in your care | Typical timing | What happens |
|---|---|---|
| Before your first dose | Baseline visit | Hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody and liver function are checked once, before treatment starts. |
| If screening is positive | Before or within the first 1–2 weeks | A hepatitis B viral load test or hepatitis C RNA test follows, sometimes with hepatology or gastroenterology input. |
| Every treatment cycle | Every 2–3 weeks, before each dose | Liver function tests are rechecked as part of standard immunotherapy monitoring, the same as for every other patient. |
| Reactivation window | Variable — reported cases cluster in the earlier months | Most reported hepatitis B reactivation on cancer treatment, when it occurs, tends to appear earlier in the course, though it can occur at any point. |
Exact timing varies from person to person — this table shows typical patterns only, not a prediction for any individual patient.
The main question
Is there a real reactivation risk with hepatitis B or C during immunotherapy?
Yes for hepatitis B, and less clearly for hepatitis C. Hepatitis B reactivation is a well-established risk with immune-suppressing cancer treatments generally, and has also been reported, though less frequently, with checkpoint inhibitor immunotherapy. Hepatitis C reactivation with immunotherapy is documented far less often in current literature.
Because immunotherapy works by altering how your immune system behaves rather than suppressing it in the way chemotherapy does, the exact reactivation risk with checkpoint inhibitors is still being defined. What is settled, and reflected in ASCO and NCCN guidance on managing patients with viral hepatitis during cancer treatment, is that screening before starting immunotherapy is now standard practice — precisely so this risk can be planned for rather than discovered mid-treatment.
This is a screening-and-monitoring conversation, not a reason to assume treatment cannot go ahead — see "Can treatment proceed?" further down this page.
Before your first dose
What screening is done first, before immunotherapy starts?
A single baseline blood draw, alongside your other pre-treatment tests, is enough to identify hepatitis B or C status in almost every patient — nothing further is needed unless a result comes back positive.
- Hepatitis B surface antigen (HBsAg) — checks for a current, active hepatitis B infection
- Hepatitis B core antibody (anti-HBc) — checks for a past or resolved hepatitis B exposure that could still reactivate
- Hepatitis C antibody — checks for past or current hepatitis C exposure
- Liver function tests (ALT, AST, bilirubin) — establishes your baseline before any treatment-related change is measured
- Follow-up viral load or RNA testing — arranged only if the initial screen is positive, to see how active the infection currently is
If you are trying to work out whether a new liver-related symptom needs urgent attention, Yellow Eyes or Dark Urine During Immunotherapy covers that symptom in more depth.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Hepatitis B or C Doesn't Have to Delay Your Cancer Care
A medical oncologist can review your hepatitis status and tell you exactly what screening and monitoring your immunotherapy will need — free, confidential, no commitment to start treatment.
The question every patient asks
Can immunotherapy proceed if I have hepatitis B or C?
In most cases, yes. A positive hepatitis B or C screen changes how treatment is planned and monitored — it is not, by itself, a reason to stop cancer treatment from going ahead.
1
Screening result is confirmed
A positive baseline result is followed up with viral load or RNA testing to see how active the infection currently is, not just whether exposure has occurred.
2
Specialist input is arranged where needed
For an active or significant infection, your oncology team typically involves a hepatologist or gastroenterologist alongside your cancer care.
3
Antiviral cover is considered
For hepatitis B in particular, antiviral medication may be started before or alongside immunotherapy to help keep the virus suppressed during treatment.
4
Immunotherapy is planned around the result
Your tumour board weighs the cancer that needs treating against your liver and viral status, and plans monitoring frequency accordingly — rather than defaulting to exclusion.
5
Monitoring continues throughout
Liver function is rechecked before every cycle for the whole course of treatment, so any flare is caught early rather than found late.
You don't have to sit with this alone
Most patients with hepatitis B or C can still be treated safely
With the right screening and monitoring in place, a medical oncologist can talk you through exactly what changes for your specific situation.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Hepatitis B or C and Immunotherapy — Your Questions Answered
Is there a reactivation risk when I have hepatitis B or C and start immunotherapy?
Yes, a reactivation risk exists, though it is far better documented with chemotherapy and antibody-based treatments than with checkpoint inhibitor immunotherapy. Hepatitis B carries the more established risk: the virus can flare or reactivate when the immune system is altered by cancer treatment, occasionally causing liver inflammation severe enough to interrupt cancer care. Hepatitis C reactivation with immunotherapy is reported far less often. Because of this, most cancer centres now follow ASCO and NCCN guidance and screen for both hepatitis B and C before starting immunotherapy, rather than waiting for a problem to appear.
What screening is done before starting immunotherapy if I have hepatitis B or C?
Before your first immunotherapy dose, a baseline blood panel typically checks hepatitis B surface antigen, hepatitis B core antibody, and hepatitis C antibody, alongside standard liver function tests. If any of these come back positive, your oncology team will usually arrange a hepatitis B viral load test or a hepatitis C RNA test to see how active the infection currently is. This screening is done once, at baseline, so your team knows your starting point and can tell a viral flare apart from a new immune reaction if your liver tests change later during treatment.
Can immunotherapy proceed if I test positive for hepatitis B or C?
In most cases, yes — a positive hepatitis B or C result does not automatically rule out immunotherapy. For hepatitis B, your team may start or continue antiviral medication alongside immunotherapy to keep the virus suppressed, based on your viral load and liver function. For hepatitis C, your oncologist weighs your current liver health and, where relevant, coordinates with a hepatologist or gastroenterologist. The final decision is individual and depends on how active the viral infection is, how well your liver is functioning, and the cancer being treated — this is not a blanket exclusion.
What are the warning signs of a hepatitis flare during immunotherapy?
Yellowing of the eyes or skin, dark urine, pale stools, new itching, loss of appetite, nausea, or unusual tiredness can all signal either a hepatitis B or C flare or a separate immune hepatitis caused by immunotherapy itself. Because these two causes can look identical from the outside and need different treatment, call your oncology team the same day any of these signs appear rather than assuming it is 'just the hepatitis acting up.' Only a blood test can tell your team which one is happening and what to do next.
Do I need antiviral medication before or during immunotherapy if I have hepatitis B?
Often, yes, if your hepatitis B is active or your viral load is significant — many oncology teams start antiviral medication before or alongside immunotherapy specifically to reduce the chance of reactivation, in line with general oncology guidance on managing patients with viral hepatitis during cancer treatment. Whether you need it, and for how long, depends on your hepatitis B viral load, liver function, and the specific regimen your hepatologist or oncologist recommends. This is a clinical decision made once your screening results are back, not something to start or stop on your own.
Is hepatitis B or C the same as the immune hepatitis immunotherapy can cause?
No — they are different problems that can look similar on the surface. Hepatitis B and C are viral infections you may already have before starting treatment, while immune hepatitis is liver inflammation caused by immunotherapy activating your own immune system against liver cells, unrelated to any virus. Both can cause the same symptoms, such as jaundice or raised liver enzymes, which is exactly why screening and monitoring exist — to work out which one is happening. Our page on immune hepatitis explains that reaction in detail.
This page is general patient-education information, not a substitute for the written guidance your own oncology team gives you based on your specific test results and treatment plan.